In PTPRD-silenced MKN74 and SNU216 gastric-cancer cells, S3I-201 (100 μM, 48 h) reduced elevated CXCL8 mRNA and secreted CXCL8. These model-specific responses do not establish that the compound acts exclusively through STAT3. [2,3]
STAT-family DNA-binding inhibition in nuclear extracts
Biochemical assay · Nuclear extracts from NIH 3T3/v-Src cells and EGF-stimulated NIH 3T3/hEGFR fibroblasts. [1]
S3I-201 inhibited STAT3 DNA binding, with weaker inhibition of STAT1-containing and STAT5 complexes in the tested extract assays. These are assay-specific comparisons, not proteome-wide selectivity evidence.
Literature-Reported Treatment Conditions
- Exposure duration
- 30 min preincubation at room temperature before labeled probe
- Method
- Cell-free nuclear-extract EMSA with hSIE or MGFe probes; band densitometry relative to vehicle control
- Vehicle
- 0.05% DMSO
- Reported limits
- Exact concentration series beyond displayed lanes and replicate count/meaning of ± for the reported IC50 estimates are not specified in the adopted passage.
Methods and source locations
Compound reported in the paper: S3I-201 (NSC 74859); Compound label in the paper: S3I-201
Research on the named compound; no validation of the current catalog lot, clinical efficacy or a salt-equivalent dose.
Results: Identification of a Chemical Probe as Inhibitor of Stat3 DNA-Binding Activity; Fig. 2A and caption; nuclear extract/EMSA methods; displayed S3I-201 structure
STAT3:STAT3 DNA binding: EMSA; reported in Results, not estimated from image. ± retained without assigning SD or SEM. — Results: Identification of a Chemical Probe as Inhibitor of Stat3 DNA-Binding Activity; Fig. 2A and caption; nuclear extract/EMSA methods; displayed S3I-201 structure
STAT1:STAT3 DNA binding: EMSA; reported in Results, not estimated from image. ± retained without assigning SD or SEM. — Results: Identification of a Chemical Probe as Inhibitor of Stat3 DNA-Binding Activity; Fig. 2A and caption; nuclear extract/EMSA methods; displayed S3I-201 structure
STAT1:STAT1 DNA binding: EMSA; reported in Results, not estimated from image. ± retained without assigning SD or SEM. — Results: Identification of a Chemical Probe as Inhibitor of Stat3 DNA-Binding Activity; Fig. 2A and caption; nuclear extract/EMSA methods; displayed S3I-201 structure
STAT5:STAT5 DNA binding: EMSA; reported in Results, not estimated from image. ± retained without assigning SD or SEM. — Results: Identification of a Chemical Probe as Inhibitor of Stat3 DNA-Binding Activity; Fig. 2A and caption; nuclear extract/EMSA methods; displayed S3I-201 structure
Glutathione reactivity and a less-reactive structural control
Biochemical assay · Cell-free HPLC chemical-stability assay with glutathione; sulfonamide analogue DB-5-112 as structural control. [2]
S3I-201 reacted rapidly with glutathione under the tested buffered conditions. DB-5-112 showed no reactivity under the same conditions. This is a chemical-reactivity result, not an in vivo half-life or cellular IC50.
Literature-Reported Treatment Conditions
- Treatment concentration
- 100 μM S3I-201 with 10 mM GSH and 10 mM TCEP-HCl in 50 mM HEPES, pH 7.4
- Exposure duration
- Time course up to 10 h
- Method
- HPLC peak-area decay; one-phase exponential fitting; method specifies three replicates
- Vehicle
- DMSO stock; 10 μL of 10 mM stock added to 990 μL reaction buffer
- Reported limits
- Replicate independence is not defined; fitted supplementary-table uncertainties were not retrieved.
Methods and source locations
Compound reported in the paper: S3I-201 (NSC 74859); Compound label in the paper: S3I-201
Research on the named compound; no validation of the current catalog lot, clinical efficacy or a salt-equivalent dose.
Results: S3I-201’s reactivity toward glutathione; Fig. 1A-C and caption; In vitro chemical stability assays
Parent-compound decay in GSH-containing buffer: Reported Results value; HPLC kinetic fit, three replicates in methods. Not estimated from plotted points. — Results: S3I-201’s reactivity toward glutathione; Fig. 1A-C and caption; In vitro chemical stability assays
Direct detection of covalent STAT3 modification
Biochemical assay · Recombinant full-length STAT3, incubated in the presence or absence of S3I-201, followed by tryptic LC-MS/MS. [2]
The main-figure spectra support covalent modification at Cys259, Cys367, Cys542 and Cys687. The authors also report Cys108, but its supplementary spectrum was not retrieved and that additional site is not adopted here. Multiple adduct sites challenge a simple selective SH2-binding interpretation.
Literature-Reported Treatment Conditions
- Treatment concentration
- 500 μM S3I-201; Results describe an 80-fold molar excess over STAT3
- Exposure duration
- 1 h at 37°C
- Method
- LC-MS/MS of digested full-length STAT3; matched incubation without S3I-201
- Vehicle
- Not specified in adopted mass-spectrometry method
- Reported limits
- Replicate count and compound-delivery solvent not specified in adopted method. Cys108 SI spectrum not retrieved.
Methods and source locations
Compound reported in the paper: S3I-201 (NSC 74859); Compound label in the paper: S3I-201
Research on the named compound; no validation of the current catalog lot, clinical efficacy or a salt-equivalent dose.
Results: Incubation of STAT3 with S3I-201, tryptic digestion and LC-MS/MS analysis; Fig. 3 and caption; Mass spectrometry methods
STAT3 covalent-adduct sites supported in main Fig. 3: LC-MS/MS fragment-ion assignments; image and Results checked. No adduct occupancy or site selectivity estimate adopted. — Results: Incubation of STAT3 with S3I-201, tryptic digestion and LC-MS/MS analysis; Fig. 3 and caption; Mass spectrometry methods
CXCL8 response in PTPRD-silenced gastric-cancer cells
Cell-based study · MKN74 and SNU216 gastric-cancer cells with stable PTPRD knockdown (shPTPRD), compared with shNS and untreated shPTPRD conditions. [3]
S3I-201 reduced CXCL8 mRNA and secreted CXCL8 elevated after PTPRD knockdown in both models. The paired expression/secretion endpoints are one coherent cellular experiment. These pharmacological responses do not establish STAT3-exclusive mediation.
Literature-Reported Treatment Conditions
- Treatment concentration
- 100 μM
- Exposure duration
- 48 h
- Method
- Separate S3I-201 treatment; CXCL8 qRT-PCR normalized to β-actin and secreted CXCL8 ELISA
- Vehicle
- Not specified in adopted locations
- Reported limits
- Exact vehicle and within-experiment technical replicate count not specified. No exact bar-height values extracted.
Methods and source locations
Compound reported in the paper: S3I-201 (NSC 74859); Compound label in the paper: S3I-201
Research on the named compound; no validation of the current catalog lot, clinical efficacy or a salt-equivalent dose.
Reagents and antibodies; Results: Loss of PTPRD activated ERK/STAT3; Fig. 4C-D and caption; RT/qRT-PCR and ELISA methods
CXCL8 mRNA after S3I-201, relative to untreated shPTPRD condition: Fig. 4C-D lower panels; qRT-PCR; caption: representative of three independent experiments, unpaired Student’s t-test. — Reagents and antibodies; Results: Loss of PTPRD activated ERK/STAT3; Fig. 4C-D and caption; RT/qRT-PCR and ELISA methods
Secreted CXCL8 after S3I-201, relative to untreated shPTPRD condition: Fig. 4C-D upper panels; ELISA; no numerical pg/mL estimate from bars. — Reagents and antibodies; Results: Loss of PTPRD activated ERK/STAT3; Fig. 4C-D and caption; RT/qRT-PCR and ELISA methods